 |
 |
| Mauna Kea's 'Cellvizio' optical biopsy platform has shown potential for non-invasive cancer diagnosis in a variety of forms of the disease - most notably the upper GI tract. Now the French company looks set to evaluate its clinical potential in lung cancer, where it has shown promise in early trials on 22 patients. Photo: Mauna Kea Technologies. |
| © 2024 SPIE Europe |
|
